drugset

drugset / Trial / NCT05439603

ANC-501 in the Treatment of Adults With Major Depressive Disorder

NCT05439603 ↗

Phase 2 Completed 15 enrolled Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc.

NaSingle-groupOpen-labelTreatment

Summary

A Phase 2 Study of ANC-501 in the treatment of adults with Major Depressive Disorder

Timeline

Start: 2022-09-19
Primary completion: 2023-08-14
Completion: 2023-10-18

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BREZIVAPTAN	Small molecule	50 mg	Oral

Indications